178 related articles for article (PubMed ID: 38138937)
1. Biomarkers and Strain Echocardiography for the Detection of Subclinical Cardiotoxicity in Breast Cancer Patients Receiving Anthracyclines.
Bhagat AA; Kalogeropoulos AP; Baer L; Lacey M; Kort S; Skopicki HA; Butler J; Bloom MW
J Pers Med; 2023 Dec; 13(12):. PubMed ID: 38138937
[TBL] [Abstract][Full Text] [Related]
2. Early detection of anthracycline- and trastuzumab-induced cardiotoxicity: value and optimal timing of serum biomarkers and echocardiographic parameters.
Díaz-Antón B; Madurga R; Zorita B; Wasniewski S; Moreno-Arciniegas A; López-Melgar B; Ramírez Merino N; Martín-Asenjo R; Barrio P; Amado Escañuela MG; Solís J; Parra Jiménez FJ; Ciruelos E; Castellano JM; Fernández-Friera L
ESC Heart Fail; 2022 Apr; 9(2):1127-1137. PubMed ID: 35106939
[TBL] [Abstract][Full Text] [Related]
3. Two-dimensional speckle tracking echocardiography predicts early subclinical cardiotoxicity associated with anthracycline-trastuzumab chemotherapy in patients with breast cancer.
Arciniegas Calle MC; Sandhu NP; Xia H; Cha SS; Pellikka PA; Ye Z; Herrmann J; Villarraga HR
BMC Cancer; 2018 Oct; 18(1):1037. PubMed ID: 30359235
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Impact of Global Longitudinal Strain and NT-proBNP on Early Development of Cardiotoxicity in Breast Cancer Patients Treated with Anthracycline-Based Chemotherapy.
Muckiene G; Vaitiekus D; Zaliaduonyte D; Zabiela V; Verseckaite-Costa R; Vaiciuliene D; Juozaityte E; Jurkevicius R
Medicina (Kaunas); 2023 May; 59(5):. PubMed ID: 37241185
[No Abstract] [Full Text] [Related]
5. Global longitudinal strain at 3 months after therapy can predict late cardiotoxicity in breast cancer.
Liu Z; Liu M; Zhong X; Qin Y; Liang T; Luo T; Yan X; Tang Z; Wang X; Liang S; Li Q; Ruan X; He W; Huang H
Cancer Med; 2023 Jun; 12(12):13374-13387. PubMed ID: 37183826
[TBL] [Abstract][Full Text] [Related]
6. Ivabradine for the Prevention of Anthracycline-Induced Cardiotoxicity in Female Patients with Primarily Breast Cancer: A Prospective, Randomized, Open-Label Clinical Trial.
Čiburienė E; Aidietienė S; Ščerbickaitė G; Sadauskienė E; Sudavičienė D; Baltruškevičienė E; Brasiūnienė B; Drobnienė M; Čelutkienė J
Medicina (Kaunas); 2023 Dec; 59(12):. PubMed ID: 38138243
[No Abstract] [Full Text] [Related]
7. Speckle tracking echocardiography predicts early subclinical anthracycline cardiotoxicity in patients with breast cancer.
Tang Q; Jiang Y; Xu Y; Xia H
J Clin Ultrasound; 2017 May; 45(4):222-230. PubMed ID: 27910996
[TBL] [Abstract][Full Text] [Related]
8. Assessment of Subclinical Deterioration of Right Ventricular Function by Three-Dimensional Speckle Tracking Echocardiography in Breast Cancer Patients Undergoing Anthracycline-Based Chemotherapy.
Xu H; Mao L; Liu H; Zhang Y; Yang J
Int J Gen Med; 2021; 14():885-893. PubMed ID: 33758535
[TBL] [Abstract][Full Text] [Related]
9. The diagnostic value of global longitudinal strain combined with cardiac biomarkers on early detection of anthracycline-related cardiac dysfunction.
Allam H; Kamal M; Bendary M; Osama A; El Eleimy HA; Bendary A
J Echocardiogr; 2023 Dec; 21(4):165-172. PubMed ID: 37453981
[TBL] [Abstract][Full Text] [Related]
10. Use of N-terminal pro-brain natriuretic peptide to assess left ventricular function after adjuvant doxorubicin therapy in early breast cancer patients: a prospective series.
Cil T; Kaplan AM; Altintas A; Akin AM; Alan S; Isikdogan A
Clin Drug Investig; 2009; 29(2):131-7. PubMed ID: 19133708
[TBL] [Abstract][Full Text] [Related]
11. Pharmacodynamic modeling of cardiac biomarkers in breast cancer patients treated with anthracycline and trastuzumab regimens.
de Vries Schultink AHM; Boekhout AH; Gietema JA; Burylo AM; Dorlo TPC; van Hasselt JGC; Schellens JHM; Huitema ADR
J Pharmacokinet Pharmacodyn; 2018 Jun; 45(3):431-442. PubMed ID: 29429038
[TBL] [Abstract][Full Text] [Related]
12. Correlation of Speckle-Tracking Echocardiography with Traditional Biomarkers in Predicting Cardiotoxicity among Pediatric Hemato-Oncology Patients: A Comprehensive Evaluation of Anthracycline Dosages and Treatment Protocols.
Ardelean AM; Olariu IC; Isac R; Jurac R; Stolojanu C; Murariu M; Toma AO; Braescu L; Mavrea A; Doros G
Children (Basel); 2023 Aug; 10(9):. PubMed ID: 37761440
[TBL] [Abstract][Full Text] [Related]
13. Deformation Analysis of Myocardial Layers Detects Early Cardiac Dysfunction after Chemotherapy in Bone Marrow Transplantation Patients: A Continuous and Additive Cardiotoxicity Process.
Paraskevaidis IA; Makavos G; Tsirigotis P; Psarogiannakopoulos P; Parissis J; Gkirkas K; Pessach I; Ikonomidis I
J Am Soc Echocardiogr; 2017 Nov; 30(11):1091-1102. PubMed ID: 28864152
[TBL] [Abstract][Full Text] [Related]
14. 2D and 3D strain for detection of subclinical anthracycline cardiotoxicity in breast cancer patients: a balance with feasibility.
Santoro C; Arpino G; Esposito R; Lembo M; Paciolla I; Cardalesi C; de Simone G; Trimarco B; De Placido S; Galderisi M
Eur Heart J Cardiovasc Imaging; 2017 May; 18(8):930-936. PubMed ID: 28379383
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Value of Cardiac Biomarkers Assessment in Combination with Myocardial 2D Strain Echocardiography for Early Detection of Anthracycline-Related Cardiac Toxicity.
Mahjoob MP; Sheikholeslami SA; Dadras M; Mansouri H; Haghi M; Naderian M; Sadeghi L; Tabary M; Khaheshi I
Cardiovasc Hematol Disord Drug Targets; 2020; 20(1):74-83. PubMed ID: 31513000
[TBL] [Abstract][Full Text] [Related]
16. Troponins and Natriuretic Peptides in Cardio-Oncology Patients-Data From the ECoR Registry.
Hinrichs L; Mrotzek SM; Mincu RI; Pohl J; Röll A; Michel L; Mahabadi AA; Al-Rashid F; Totzeck M; Rassaf T
Front Pharmacol; 2020; 11():740. PubMed ID: 32508657
[TBL] [Abstract][Full Text] [Related]
17. Decline in Left Ventricular Ejection Fraction Following Anthracyclines Predicts Trastuzumab Cardiotoxicity.
Goel S; Liu J; Guo H; Barry W; Bell R; Murray B; Lynch J; Bastick P; Chantrill L; Kiely BE; Abdi E; Rutovitz J; Asghari R; Sullivan A; Harrison M; Kohonen-Corish M; Beith J
JACC Heart Fail; 2019 Sep; 7(9):795-804. PubMed ID: 31401102
[TBL] [Abstract][Full Text] [Related]
18. Myocardial dysfunction in long-term breast cancer survivors treated at ages 40-50 years.
Jacobse JN; Steggink LC; Sonke GS; Schaapveld M; Hummel YM; Steenbruggen TG; Lefrandt JD; Nuver J; Crijns APG; Aleman BMP; van der Meer P; Gietema JA; van Leeuwen FE
Eur J Heart Fail; 2020 Feb; 22(2):338-346. PubMed ID: 31696625
[TBL] [Abstract][Full Text] [Related]
19. Changes in Cardiovascular Biomarkers With Breast Cancer Therapy and Associations With Cardiac Dysfunction.
Demissei BG; Hubbard RA; Zhang L; Smith AM; Sheline K; McDonald C; Narayan V; Domchek SM; DeMichele A; Shah P; Clark AS; Fox K; Matro J; Bradbury AR; Knollman H; Getz KD; Armenian SH; Januzzi JL; Tang WHW; Liu P; Ky B
J Am Heart Assoc; 2020 Jan; 9(2):e014708. PubMed ID: 31959034
[TBL] [Abstract][Full Text] [Related]
20. Early Detection and Prediction of Anthracycline-Induced Cardiotoxicity - A Prospective Cohort Study.
Inoue K; Machino-Ohtsuka T; Nakazawa Y; Iida N; Sasamura R; Bando H; Chiba S; Tasaka N; Ishizu T; Murakoshi N; Xu D; Sekine I; Tajiri K
Circ J; 2024 Apr; 88(5):751-759. PubMed ID: 38462534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
